ProCE Banner Activity

Peginterferon α-2a in Essential Thrombocythemia and Polycythemia Vera: 7-Year Efficacy and Safety Data

Slideset Download
Conference Coverage
PegIFN2a is effective treatment for ET/PV as shown by favorable long-term hematologic and molecular responses.

Released: December 10, 2015

Expiration: December 08, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen